Over half of the mutations in UGT genes in tumors are predicted to encode truncated proteins or variant proteins with deleterious amino acid substitutions that likely influence the capacity of cancer cells to metabolize anticancer drugs and pro/anti-cancer signaling molecules through the UGT conjugation pathway. This evidence concerns the gene SLC35A2 and cancer.